Fennec (FENC) CCO Terry L. Evans Receives 168 Shares

What Happened
Terry L. Evans, Chief Commercial Officer of Fennec Pharmaceuticals, was reported to have acquired 168 shares on 2026-07-31. The shares were recorded at $0.00 per share (no cash exchanged) and are described as shares released from restriction—i.e., part of a prior award rather than an open-market purchase.

Key Details

• Transaction date and price: 2026-07-31; 168 shares at $0.00 per share.
• Filing date: Form 4 filed 2026-08-03 (within the standard two-business-day reporting window).
• Shares owned after transaction: Not specified in this Form 4.
• Footnote: F1 — shares released from restrictions from an award granted 3/28/2025.
• Transaction type: Award/release of restricted stock (code A).

Context
This was a release of previously awarded restricted shares, a common form of compensation/vesting and not an open-market buy or sell. Such releases reflect vesting or fulfillment of award conditions and do not by themselves indicate the insider is buying (bullish) or selling (realizing proceeds).